Paul Nathan
University College Hospital · 475 works · 31,067 citations · h-index 70
Top works
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
- Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
- Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
- Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker
- Epithelial Ovarian Cancer: A Review of Current Management
- Revised U.K. guidelines for the management of cutaneous melanoma 2010
- Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- Revised UK guidelines for the management of cutaneous melanoma 2010
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- Metastatic disease from uveal melanoma: treatment options and future prospects